Redeye comments on the Q1 report from Vicore, that did not offer any surprises. We provide a brief comment on the financials and highlight the most important events during the period. Furthermore, we expand on yesterday’s announcement of a new program (VP04) focusing on a digital therapy for IPF patients. Our Base case remains at SEK 62 per share at this stage.